A phase II trial of huperzine A in mild to moderate Alzheimer disease

Rafii, Michael S.; Walsh, Sally; Little, John T.; Behan, K A; Reynolds, Brigid; Ward, Carwyn; Jin, Shelia; Thomas, Ronald G.; Aisen, Paul S.

doi:10.1212/wnl.0b013e318216eb7b

Cited by 201 publications

(130 citation statements)

References 17 publications

Supporting

Mentioning

128

Contrasting

Unclassified

Order By: Relevance

“…Preclinical studies suggest possible neuroprotective mechanisms. A recent Phase II trial in the USA failed to demonstrate efficacy of the usual dose used in China, 200 mcg twice daily, but did provide some evidence of cognitive enhancement at twice this dose (Rafii et al 2011). …”

Section: Cerebrolysinmentioning

confidence: 99%

Symptomatic and Nonamyloid/Tau Based Pharmacologic Treatment for Alzheimer Disease

Aisen

Cummings

Schneider

2011

Cold Spring Harbor Perspectives in Medicine

Self Cite

View full text Add to dashboard Cite

In this work we consider marketed drugs for Alzheimer disease (AD) including acetylcholinesterase inhibitors (AChE-Is) and antiglutamatergic treatment involving the N-methyl-D-aspartate (NMDA) receptor. We discuss medications and substances available for use as cognitive enhancers that are not approved for AD or cognitive impairment, and other neurotransmitter-related therapies in development or currently being researched. We also review putative therapies that aim to slow disease progression by mechanisms not directly related to amyloid or tau. REGULATORY LANDSCAPE AND CLINICAL TRIALS

show abstract

Section: Cerebrolysinmentioning

confidence: 99%

Symptomatic and Nonamyloid/Tau Based Pharmacologic Treatment for Alzheimer Disease

Aisen

Cummings

Schneider

2011

Cold Spring Harbor Perspectives in Medicine

Self Cite

View full text Add to dashboard Cite

show abstract

“…Numerous studies have shown that multiple herbs and herbal extracts of Traditional Chinese Medicine (TCM) are effective in the treatment of central nervous system diseases such as Parkinson's disease (Hong et al, 2014), Alzheimer disease (Rafii et al, 2011) and spinal cord injury (Fan et al, 2013). Rhodiola is a widely used TCM herb that has been shown to improve cognitive function, reduce mental fatigue, decrease free radicals, and enhance learning and memory (Darbinyan et al, 2000;Shevtsov et al, 2003).…”

Section: Introductionmentioning

confidence: 99%

Endoplasmic Reticulum Stress and NF-κB Pathway in Salidroside Mediated Neuroprotection: Potential of Salidroside in Neurodegenerative Diseases

Wang

Lou

et al. 2017

Am. J. Chin. Med.

View full text Add to dashboard Cite

Microglial activation leads to increased production of proinflammatory enzymes and cytokines, which is considered to play crucial role in neurodegenerative diseases, however there are only a few drugs that target microglia activation. Recent studies have indicated that the Traditional Chinese Medicine, salidroside (Sal), exerted anti-inflammatory effects. According to this evidence, our present study aims to explore the effect of the Sal (a phenylpropanoid glycoside compound which is isolated from rhodiola), on microglia activation in lipopolysaccharide (LPS)-stimulated BV-2 cells. Our results showed that Sal could significantly inhibit the excessive production of Nitric Oxide (NO) and Prostaglandin E2 (PGE 2 ) in LPS-stimulated BV2 cells. Moreover, Sal treatment could suppress the mRNA and protein expressions of inflammatory enzymes, including Inducible Nitric Oxide Synthase (iNOS) and Cyclooxygenase-2 (COX-2). The mechanisms may be related to the inhibition of the activation of Nuclear Factor-kappaB (NF-κB) and endoplasmic reticulum stress. Our study demonstrated that salidroside could inhibit lipopolysaccharide-induced microglia The American Journal of Chinese Medicine, Vol. 45, No. 7, 1459-1475 © 2017 activation via the inhibition of the NF-κB pathway and endoplasmic reticulum stress, which makes it a promising therapeutic agent for human neurodegenerative diseases.

show abstract

“…Given the potential roles of cholinergic agonists (9,10) and antagonists of NMDA-subtype glutamate receptors (10,11) in the treatment of neuropathic pain, we hypothesized that [-]-huperzine A (HUP-A) (Fig. 1A), a naturally occurring Lycopodium alkaloid isolated from the Chinese club moss, Huperzia serrata (Fig.…”

mentioning

confidence: 99%

Alleviation of chronic pain following rat spinal cord compression injury with multimodal actions of huperzine A

Thakor

Han

et al. 2013

Proc. Natl. Acad. Sci. U.S.A.

View full text Add to dashboard Cite

Significance Neuropathic pain, one of the most debilitating sequelae of neurotrauma, is an unmet clinical need for at least 40% of patients with spinal cord injury (SCI). We demonstrate that [-]-huperzine A (HUP-A), a naturally occurring Lycopodium alkaloid isolated from the Chinese club moss, Huperzia serrata , with potent reversible inhibitory action on acetylcholinesterase and N -methyl- D -aspartate glutamate receptors, offers an exceptional prospect for multimodal treatment of SCI-induced neuropathic pain in rats. HUP-A restores homeostasis of central sensory neurocircuitry without invoking drug tolerance and dependence or respiratory suppression. We therefore conclude that multimodal actions provide a fresh translational approach to reduce chronic pain.

show abstract

A phase II trial of huperzine A in mild to moderate Alzheimer disease

Cited by 201 publications

References 17 publications

Symptomatic and Nonamyloid/Tau Based Pharmacologic Treatment for Alzheimer Disease

Symptomatic and Nonamyloid/Tau Based Pharmacologic Treatment for Alzheimer Disease

Endoplasmic Reticulum Stress and NF-κB Pathway in Salidroside Mediated Neuroprotection: Potential of Salidroside in Neurodegenerative Diseases

Alleviation of chronic pain following rat spinal cord compression injury with multimodal actions of huperzine A

Contact Info

Product

Resources

About